Clinical Trials Browser

Phase 1 × Carcinoma × GV1001 peptide × Clear all

NCT01223209 2012-01-11

A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma

Phase 1 Completed

Carcinoma, Neoplasms